Although established biomarkers such as B-type natriuretic peptide (BNP), N-terminal pro–B-type natriuretic peptide (NT-proBNP), cardiac troponin (cTnT), and creatine kinase are routinely employed for the diagnosis of acute myocardial infarction (AMI) due to their high sensitivity and specificity, they may not adequately reflect the pathophysiological processes underlying MIRI. Here, NPPB is linked to myocardial infarction.